Vertex to acquire Crinetics for ~<meta name=

0B all-cash play to add endocrinology as its fifth commercial pillar behind cystic fibrosis, pain, sickle cell and kidney." /> 0B in cash at $85/share on Monday July 6 — CRNX +98.8% to $83.53 on 102% premium as VRTX slips ~-2.5% AH; deal adds PALSONIFY acromegaly franchise and Phase 3 atumelnant, closes Q3 2026" /> 0B all-cash play to add endocrinology as its fifth commercial pillar behind cystic fibrosis, pain, sickle cell and kidney." /> 0B in cash at $85/share on Monday July 6 — CRNX +98.8% to $83.53 on 102% premium as VRTX slips ~-2.5% AH; deal adds PALSONIFY acromegaly franchise and Phase 3 atumelnant, closes Q3 2026" /> 0B all-cash play to add endocrinology as its fifth commercial pillar behind cystic fibrosis, pain, sickle cell and kidney." />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.